Company: BSX
Filing Date: 2025-03-19
Form Type: DEF 14A
Source: 0000885725-25-000017
Chunk: 45

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-03-19
Form: DEF 14A
Chunk 45
---
 Non-Employee Director Deferred Compensation Plan. The interest rate used under the plan each year is the Moody’s Composite Yield on Seasoned Corporate Bonds for the month of September of the preceding year. For 2024, the interest rate used under the p la n was 5.73%, the Moody’s rate in September 2023. Under SEC rules, interest on non-qualified deferred compensation is considered “above-market” if the interest rate exceeds 120% of the federal long-term interest rate, with compounding at the rate that corresponds most closely to the rate under the plan, at the time the interest rate or formula is set. For 2024, 120% of the applicable federal long-term interest rate was 5.04%.

(6) Ms. Connors and Mr. Roux did not stand for reelection to our Board at our May 2, 2024 Annual Meeting of Stockholders when their term ended.

(7) Mr. Habiger joined our Board in July 2024, and compensation for his service during the term reflects proration from the effective date of his appointment until the date of the next annual meeting.

(8) Dr. Pegus joined our Board in May 2024, and compensation for her service during the term reflects proration from the effective date of her appointment until the date of the next annual meeting.

#### 382025 Proxy Statement

#### Our Executive Officers
Below we provide biographical information for each of our Executive Officers other than Mr. Mahoney, whose biographical information is presented in Proposal 1: Election of Directors on page 15 .

| Daniel J. Brennan                                   
 Executive Vice Presidentand Chief Financial Officer |     | Mr. Brennan, age 59, is our Executive Vice President and Chief Financial Officer, a position he has held since January 2014. In this role, he leads several Company functions, including Global Controllership, Global Internal Audit, Corporate Finance, Treasury, Corporate Tax, Investor Relations, and Corporate Business Development. Since joining the Company in 1996, he has held roles of increasing responsibility, including Senior Vice President and Corporate Controller (2010 to 2014); VP Assistant Corporate Controller (2009); VP of Finance for Worldwide Financial and Strategic Planning (2008), Investor Relations (2006 to 2007), International Finance (2005 to 2006) and Cardiology (2001 to 2005); Group Controller of the Non-Vascular Business (1999 to 2020); and Controller of the Med